Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort.

OBJECTIVE To assess the prevalence of the metabolic syndrome (MetS) in two independent Finnish study cohorts. RESEARCH DESIGN AND METHODS The prevalence of the MetS by modified World Health Organization criteria was analyzed in different categories of glucose tolerance in a cross-sectional, population-based sample of 2,049 individuals (FINRISK) aged 45-64 years and in 522 participants of the Finnish Diabetes Prevention Study (DPS) with impaired glucose tolerance (IGT). RESULTS In the FINRISK cohort, the MetS was present in 38.8% of the men and 22.2% of the women. The prevalence was 14.4 and 10.1% in subjects with normal glucose tolerance, 74.0 and 52.2% in subjects with impaired fasting glucose, 84.8 and 65.4% in subjects with IGT, and 91.5 and 82.7% in subjects with type 2 diabetes in men and women, respectively. Among women, the prevalence of the MetS increased with increasing age. In the DPS cohort, the MetS was present in 78.4% of the men and 72.2% of the women with IGT. CONCLUSIONS The MetS was extremely common in middle-aged subjects The high prevalence in men was mostly due to their high waist-to-hip ratio. The prevalence of the MetS increased in both sexes with deterioration in glucose regulation. Approximately 75% of the subjects with IGT had the MetS. Because the syndrome includes the major risk factors for atherosclerotic vascular diseases and is the major antecedent for type 2 diabetes, concerted preventive action should be targeted to control all the features of the MetS.

[1]  J. Ekoé,et al.  Diagnosis and Classification of Diabetes Mellitus , 2019, Encyclopedia of Endocrine Diseases.

[2]  H. King,et al.  Primary prevention of Type 2 (non-insulin-dependent) diabetes mellitus , 2004, Diabetologia.

[3]  S. Haffner,et al.  The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. , 2003, Diabetes care.

[4]  Z. Bloomgarden American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. , 2003, Diabetes care.

[5]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[6]  L. Niskanen,et al.  Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. , 2002, American journal of epidemiology.

[7]  P. Nilsson,et al.  Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. , 2002, Diabetes & metabolism.

[8]  M. Uusitupa,et al.  Lifestyles matter in the prevention of type 2 diabetes. , 2002, Diabetes care.

[9]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[10]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[11]  L. Groop,et al.  The metabolic syndrome influences the risk of chronic complications in patients with Type II diabetes , 2001, Diabetologia.

[12]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[13]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[14]  T. Valle,et al.  The Finnish Diabetes Prevention Study , 2000, British Journal of Nutrition.

[15]  M. Laakso,et al.  Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes , 2000, Diabetologia.

[16]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[17]  T. Valle,et al.  Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland Study design and 1-year interim report on the feasibility of the lifestyle intervention programme , 1999, Diabetologia.

[18]  B. Balkau,et al.  Comment on the provisional report from the WHO consultation , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[19]  M. Trevisan,et al.  Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. , 1998, American journal of epidemiology.

[20]  S. Kiechl,et al.  Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. , 1998, Diabetes.

[21]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[22]  A. Amos,et al.  The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010 , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[23]  E. Vartiainen,et al.  Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland , 1994, BMJ.

[24]  J. Tuomilehto,et al.  Primary prevention of non-insulin-dependent diabetes mellitus. , 1992, Diabetes/metabolism reviews.

[25]  R. Hamman Genetic and environmental determinants of non-insulin-dependent diabetes mellitus (NIDDM). , 1992, Diabetes/metabolism reviews.

[26]  S. Haffner,et al.  Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.

[27]  V. Salomaa,et al.  Acute myocardial infarction (AMI) in Finland--baseline data from the FINMONICA AMI register in 1983-1985. , 1992, European heart journal.

[28]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[29]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[30]  P. Zimmet Primary Prevention of Diabetes Mellitus , 1988, Diabetes Care.

[31]  Henry Wl Perspectives in diabetes. , 1962 .